Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Mugusi, Sabina ^a,b   Ngaimisi, Eliford ^c,d   Janabi, Mohamed ^d   Minzi, Omary ^d   Bakari, Muhammad ^d   Riedel, Klaus Dieter ^e   Burhenne, Juergen ^e   Lindquist, Lars ^c   Mugusi, Ferdinand ^d   Sandstrom, Eric ^a   Aklillu, Eleni ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; EFAVIRENZ; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LAMIVUDINE; LIVER ENZYME; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; RIFAMPICIN; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; DEMOGRAPHY; DISEASE COURSE; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TANZANIA; TOXIC HEPATITIS; TREATMENT DURATION; TUBERCULOSIS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; COINFECTION; DEMOGRAPHY; DRUG-INDUCED LIVER INJURY; HAPLOTYPES; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIVER; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TANZANIA; TREATMENT OUTCOME; TUBERCULOSIS;

HEPATITIS C VIRUS;

EID: 84863830162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040180     Document Type: Article

References (52)

1. Kwara A, Flanigan TP, Carter EJ, (2005) Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis 9: 248-257.
2. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. Aids 16: 75-83.
3. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, et al. (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23: 192-202.
4. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, et al. (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174: 935-952.
5. Wares DF, Singh S, Acharya AK, Dangi R, (2003) Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. Int J Tuberc Lung Dis 7: 327-335.
6. WHO Library Cataloguing-in-Publication Data: Treatment of tuberculosis: guidelines- 4th ed. http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf (accessed 28 May 2012). WHO/HTM/TB/2009.420.
7. Abrescia N, D'Abbraccio M, Figoni M, Busto A, Butrico E, et al. (2002) Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus co-infection. J Antimicrob Chemother 50: 763-765.
8. Turkova A, Ball C, Gilmour-White S, Rela M, Mieli-Vergani G, (2009) A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation. J Antimicrob Chemother 63: 623-625.
9. Lamar ZS, Nunez M, (2011) Higher Risk of Severe Drug-Induced Liver Injury among Hispanic HIV-Infected Patients after Initiation of Highly Active Antiretroviral Therapy. J Int Assoc Physicians AIDS Care (Chic) 10: 183-186.
10. Desta Z, Saussele T, Ward B, Blievernicht J, Li L, et al. (2007) Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8: 547-558.
11. Gounden V, van Niekerk C, Snyman T, George JA, (2010) Presence of the CYP2B6 516G>T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 7: 32.
12. Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, et al. (2011) Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. Clin Pharmacol Ther 90: 406-413.
13. Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, et al. (2010) Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 88: 676-684.
14. Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, et al. (2011) Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. The Journal of antimicrobial chemotherapy 66: 2350-2361.
15. Mukonzo JK, Roshammar D, Waako P, Andersson M, Fukasawa T, et al. (2009) A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 68: 690-699.
16. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391.
17. Mirghani RA, Sayi J, Aklillu E, Allqvist A, Jande M, et al. (2006) CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics 16: 637-645.
18. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, et al. (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54: 1609-1616.
19. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Pinan MA, Garcia-Miguel P, et al. (2011) Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57: 612-619.
20. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, et al. (2005) The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 78: 551-558.
21. Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, Konig S, et al. (2011) Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler(R)-based method. Eur J Clin Pharmacol 10.1007/s00228-011-1065-9.
22. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, et al. (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41: 816-819.
23. Russmann S, Jetter A, Kullak-Ublick GA, (2010) Pharmacogenetics of drug-induced liver injury. Hepatology 52: 748-761.
24. Stine JG, Lewis JH, (2011) Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol 7: 875-890.
25. Aklillu E, Dandara C, Bertilsson L, Masimirembwa C, (2007) Pharmacogenetics of Cytochrome P450s in African Populations: Clinical and Molecular Evolutionary Implications. In: Suarez-Kurtz G, editors. pp. 99-119 editor. Pharmacogenomics in Admixed Populations. Austin, TX: Landes Bioscience.
26. Mugusi SF, Ngaimisi E, Janabi MY, Mugusi FM, Minzi OM, et al. (2012) Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania. Antivir Ther 17: 265-274.
27. Benichou C, (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11: 272-276.
28. Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, et al. (2008) Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS ONE 3: e1809.
29. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, et al. (2011) High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 10.1038/tpj.2011.34.
30. Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, et al. (2011) Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients. PLoS One 6: e27810.
31. Soleman N, Chandramohan D, Shibuya K, (2006) Verbal autopsy: current practices and challenges. Bull World Health Organ 84: 239-245.
32. Lopman B, Cook A, Smith J, Chawira G, Urassa M, et al. (2010) Verbal autopsy can consistently measure AIDS mortality: a validation study in Tanzania and Zimbabwe. J Epidemiol Community Health 64: 330-334.
33. Kalyesubula R, Kagimu M, Opio KC, Kiguba R, Semitala CF, et al. (2011) Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci 11: 16-23.
34. Ocama P, Castelnuovo B, Kamya MR, Kirk GD, Reynolds SJ, et al. (2010) Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS 21: 553-557.
35. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, et al. (2007) Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 21: 1301-1308.
36. Hoffmann CJ, Fielding KL, Charalambous S, Sulkowski MS, Innes C, et al. (2008) Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS 22: 67-74.
37. Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, et al. (2005) Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 10: 489-498.
38. Tostmann A, Boeree MJ, Harries AD, Sauvageot D, Banda HT, et al. (2007) Short communication: antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi. Trop Med Int Health 12: 852-855.
39. Tostmann A, van den Boogaard J, Semvua H, Kisonga R, Kibiki GS, et al. (2010) Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients. Trop Med Int Health 15: 268-272.
40. Shipton LK, Wester CW, Stock S, Ndwapi N, Gaolathe T, et al. (2009) Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis 13: 360-366.
41. Cohen K, Meintjes G, (2010) Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS 5: 61-69.
42. Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, et al. (2008) High prevalence of the CYP2B6 516G->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64: 357-365.
43. Matee MI, Magesa PM, Lyamuya EF, (2006) Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health 6: 21.
44. Anderson AM, Mosunjac MB, Palmore MP, Osborn MK, Muir AJ, (2010) Development of fatal acute liver failure in HIV-HBV coinfected patients. World J Gastroenterol 16: 4107-4111.
45. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, et al. (1999) Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 180: 607-613.
46. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, et al. (2003) An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 17: F7-10.
47. Mankhatitham W, Lueangniyomkul A, Manosuthi W, (2011) Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. Southeast Asian J Trop Med Public Health 42: 651-658.
48. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, et al. (1998) Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157: 1871-1876.
49. Patel A, Patel K, Patel J, Shah N, Patel B, et al. (2004) Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 37: 1166-1169.
50. Singla R, Sharma SK, Mohan A, Makharia G, Sreenivas V, et al. (2010) Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 132: 81-86.
51. Pukenyte E, Lescure FX, Rey D, Rabaud C, Hoen B, et al. (2007) Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis 11: 78-84.
52. Figueroa SC, de Gatta MF, Garcia LH, Hurle AD, Bernal CB, et al. (2010) The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. Ther Drug Monit 32: 579-585.